Physician profile
Daniel Yang Lu
NPI 1609286301
$3,175.84
in general payments reported to CMS, 2019-2025
15 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $337 · 2021: $410 · 2022: $236 · 2023: $1,005 · 2024: $501 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,780.30 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $284.11 | 2023-2024 | Impella |
| Medtronic Vascular, INC. | $266.21 | 2019-2020 | |
| Shockwave Medical, INC | $204.96 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals Lp | $196.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $147.36 | 2019-2021 | |
| Boston Scientific Corporation | $52.03 | 2019 | |
| Lantheus Medical Imaging, INC. | $44.04 | 2019 | |
| Pfizer INC. | $43.62 | 2019-2020 | |
| Amgen INC. | $42.71 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.45 | 2019 | |
| La Jolla Pharmaceutical Company | $25.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.32 | 2020 | |
| Astellas Pharma US INC | $22.21 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.